Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells

Molecular Oncology

Volumn 10, Issue 9, 2016, Pages 1415-1429

  Mehdawi, Lubna M ^a   Prasad, Chandra Prakash ^a   Ehrnström, Roy ^a   Andersson, Tommy ^a   Sjölander, Anita ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

15 PGDH; Colon cancer; JNK; WNT 5A; Catenin

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; BETA CATENIN; MESSENGER RNA; MUCIN 2; STRESS ACTIVATED PROTEIN KINASE; WNT5A PROTEIN; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; FOXY-5 PEPTIDE; OLIGOPEPTIDE; WNT5A PROTEIN, HUMAN;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; COLON CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; BREAST TUMOR; CACO-2 CELL LINE; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HT-29 CELL LINE; KAPLAN MEIER METHOD; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CACO-2 CELLS; CELL DIFFERENTIATION; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; KAPLAN-MEIER ESTIMATE; MICE, NUDE; OLIGOPEPTIDES; SIGNAL TRANSDUCTION; UP-REGULATION; WNT-5A PROTEIN;

EID: 84994336855     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.07.011     Document Type: Article

References (48)

1. Backlund, M.G., Mann, J.R., Holla, V.R., et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 280 (2005), 3217–3223.
2. Blanc, E., Roux, G.L., Benard, J., et al. Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene 24 (2005), 1277–1283.
3. Brown, J.R., DuBois, R.N., COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23 (2005), 2840–2855.
4. Celis, J.E., Gromov, P., Cabezon, T., et al. 15-Prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol. Cell. Prot. MCP 7 (2008), 1795–1809.
5. Chen, E.Y., DeRan, M.T., Ignatius, M.S., et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/beta-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 5349–5354.
6. Cheng, R., Sun, B., Liu, Z., et al. Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition. J. Cell. Physiol. 229:12 (2014), 1908–1917.
7. Choi, S.H., Kim, B.G., Robinson, J., et al. Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis. J. Clin. Invest. 124 (2014), 2472–2482.
8. Dejmek, J., Dejmek, A., Safholm, A., et al. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 65 (2005), 9142–9146.
9. Dejmek, J., Leandersson, K., Manjer, J., et al. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin. Cancer Res. 11 (2005), 520–528.
10. Ensor, C.M., Tai, H.H., 15-Hydroxyprostaglandin dehydrogenase. J. Lipid Med. Cell Signal. 12 (1995), 313–319.
11. Grady, W.M., Markowitz, S.D., Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics Hum. Genet. 3 (2002), 101–128.
12. Greenland, K.J., Jantke, I., Jenatschke, S., et al. The human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene promoter is controlled by Ets and activating protein-1 transcription factors and progesterone. Endocrinology 141 (2000), 581–597.
13. Huxley, R.R., Ansary-Moghaddam, A., Clifton, P., et al. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int. J. Cancer 125 (2009), 171–180.
14. Jonsson, M., Andersson, T., Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. J. Cell Sci. 114 (2001), 2043–2053.
15. Jonsson, M., Dejmek, J., Bendahl, P.O., et al. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 62 (2002), 409–416.
16. Kikuchi, A., Yamamoto, H., Sato, A., et al. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol. 204 (2012), 17–33.
17. Kremenevskaja, N., von Wasielewski, R., Rao, A.S., et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24 (2005), 2144–2154.
18. Lehtinen, L., Vainio, P., Wikman, H., et al. 15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. J. Pathol. 226 (2012), 674–686.
19. Li, M., Xie, J., Cheng, L., et al. Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene. Cancer Invest. 26 (2008), 905–912.
20. Liang, H., Chen, Q., Coles, A.H., et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell. 4:5 (2003), 349–360.
21. Magnusson, C., Mezhybovska, M., Lörinc, E., et al. Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. Eur. J. Cancer 46 (2010), 826–835.
22. Markowitz, S.D., Bertagnolli, M.M., Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 361 (2009), 2449–2460.
23. Myung, S.J., Rerko, R.M., Yan, M., et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 12098–12102.
24. Nomachi, A., Nishita, M., Inaba, D., et al. Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A. J. Biol. Chem. 283 (2008), 27973–27981.
25. Pham, H., Chen, M., Li, A., et al. Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors. Pancreas 39 (2010), 332–339.
26. Prasad, C.P., Chaurasiya, S.K., Axelsson, L., et al. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Mol. Oncol. 7 (2013), 870–883.
27. Säfholm, A., Leandersson, K., Dejmek, J., et al. A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J. Biol. Chem. 281 (2006), 2740–2749.
28. Säfholm, A., Tuomela, J., Rosenkvist, J., et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin. Cancer Res. 14 (2008), 6556–6563.
29. Salim, T., Sjölander, A., Sand-Dejmek, J., Nuclear expression of glycogen synthase kinase-3beta and lack of membranous beta-catenin is correlated with poor survival in colon cancer. Int. J. Cancer 133 (2013), 807–815.
30. Sand-Dejmek, J., Ehrnström, R., Berglund, P., et al. The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women. PLoS One, 8, 2013, e70890.
31. Siegel, R., Desantis, C., Jemal, A., Colorectal cancer statistics, 2014. CA – Cancer J. Clin. 64 (2014), 104–117.
32. Sinicrope, F.A., Gill, S., Role of cyclooxygenase-2 in colorectal cancer. Cancer Met. Rev. 23 (2004), 63–75.
33. Smartt, H.J., Greenhough, A., Ordonez-Moran, P., et al. beta-catenin negatively regulates expression of the prostaglandin transporter PGT in the normal intestinal epithelium and colorectal tumour cells: a role in the chemopreventive efficacy of aspirin?. Br. J. Cancer 107 (2012), 1514–1517.
34. Smartt, H.J., Greenhough, A., Ordonez-Moran, P., et al. Beta-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells. Gut 61 (2012), 1306–1314.
35. Song, H.J., Myung, S.J., Kim, I.W., et al. 15-Hydroxyprostaglandin dehydrogenase is downregulated and exhibits tumor suppressor activity in gastric cancer. Cancer Invest. 29 (2011), 257–265.
36. Syed Khaja, A.S., Helczynski, L., Edsjo, A., et al. Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One, 6, 2011, e26539.
37. Tai, H.H., Tong, M., Ding, Y., 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prost. Lipid Med. 83 (2007), 203–208.
38. Taupin, D., Podolsky, D.K., Mitogen-activated protein kinase activation regulates intestinal epithelial differentiation. Gastroenterology 116 (1999), 1072–1080.
39. Tenesa, A., Dunlop, M.G., New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat. Rev. Genet. 10 (2009), 353–358.
40. Topol, L., Jiang, X., Choi, H., et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J. Cell Biol. 162 (2003), 899–908.
41. Triantafillidis, J.K., Nasioulas, G., Kosmidis, P.A., Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. Int. J. Cancer Res. Treat. 29 (2009), 2727–2737.
42. Tseng-Rogenski, S., Gee, J., Ignatoski, K.W., et al. Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am. J. Pathol. 176 (2010), 1462–1468.
43. Turini, M.E., DuBois, R.N., Cyclooxygenase-2: a therapeutic target. Annu. Rev. Med. 53 (2002), 35–57.
44. Wang, C., Zhao, Y., Su, Y., et al. C-Jun N-terminal kinase (JNK) mediates Wnt5a-induced cell motility dependent or independent of RhoA pathway in human dental papilla cells. PLoS One, 8, 2013, e69440.
45. Wang, D., Fu, L., Sun, H., et al. Prostaglandin E promotes colorectal cancer stem cell expansion and metastasis in mice. Gastroenterology 149:7 (2015), 1884–1895.
46. White, B.D., Chien, A.J., Dawson, D.W., Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology 142 (2012), 219–232.
47. Yan, M., Rerko, R.M., Platzer, P., et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 17468–17473.
48. Ying, J., Li, H., Yu, J., et al. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin. Cancer Res. 14 (2008), 55–61.